Allan Young

Professor Allan Young is a leading academic in Psychological Medicine at King’s College London’s Institute of Psychiatry, Psychology and Neuroscience (IoPPN). He holds the Chair of Mood Disorders and directs the Centre for Affective Disorders. His career includes academic roles at Oxford University, Newcastle University, University of British Columbia, and Imperial College London. His research focuses on mood disorders, psychopharmacology, and treatment efficacy, with over 400 peer-reviewed publications and authored/co-authored books like Bipolar Disorders: Basic Mechanisms and Therapeutic Implications.

Young’s work spans clinical trials, pharmacogenomics, and neuropsychiatric interventions. He has received grants from the UK Medical Research Council, Wellcome Trust, and NIH. His research emphasizes bipolar disorder, antidepressant resistance, and lithium therapy. Notably, he was ranked in Thomson Reuters’ 2014 Highly Cited Researchers list for Psychiatry/Psychology, placing him in the top 1% globally by citation impact.

He serves as President of the British Association of Psychopharmacology and chairs committees at the Royal College of Psychiatrists. Professional activities include editorial roles, charity leadership (Bipolar UK, Drug Safety Research Unit), and advocacy for stratified psychiatry. Current projects include trials on ketamine for anorexia, psychedelic therapies for substance use, and neuroimaging studies of bipolar disorder.

His work integrates clinical, genetic, and neurobiological approaches to mental health, with a focus on translational research and patient-centered outcomes. Key themes include personalized medicine, treatment-resistant depression, and cognitive remediation in mood disorders.